Janssen Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for INVOKANA ® (canagliflozin) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) Based on Landmark CANVAS Program
Filing includes data on the combined risk reduction of cardiovascular death, myocardial infarction and stroke in patients with type 2 diabetes
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Canagliflozin | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Attack | Invokana | New Drug Applications | Pharmaceuticals | Stroke